OSTX Q2: significant 2.5‐yr OS result; mid‐Sept FDA/MHRA statistic meetings and $5M first close of up to $10M financing

OS Therapies (OSTX) reported a Q2 net operating loss of $8.576M ($0.20/share) and says it raised minimally dilutive capital plus secured up to $10M of debt financing backed by U.K. VAT refunds and refundable R&D tax credits, with $5M funded at an Aug. 10 first close to extend runway into 2027. Clinically and regulatorily, OST‐HER2 showed a statistically significant 2.5‐year overall survival benefit (75% vs. 47%, p=0.003), the company has achieved multi‐agency alignment on 3‐year OS and biomarker endpoints and ATMP designation from EMA, and has Type C/Statistical Methods meetings with FDA and MHRA in mid‐September to lock the statistical analysis plan and confirmatory Phase 3 design ahead of BLA/CMAA submissions.